Tyler Alban

1.8k total citations
33 papers, 938 citations indexed

About

Tyler Alban is a scholar working on Oncology, Immunology and Genetics. According to data from OpenAlex, Tyler Alban has authored 33 papers receiving a total of 938 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 14 papers in Immunology and 13 papers in Genetics. Recurrent topics in Tyler Alban's work include Glioma Diagnosis and Treatment (13 papers), Immune cells in cancer (12 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Tyler Alban is often cited by papers focused on Glioma Diagnosis and Treatment (13 papers), Immune cells in cancer (12 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Tyler Alban collaborates with scholars based in United States, China and Germany. Tyler Alban's co-authors include Justin D. Lathia, Michael A. Vogelbaum, Defne Bayık, Alvaro G. Alvarado, James S. Hale, Erin E. Mulkearns-Hubert, Daniel J. Silver, Manmeet S. Ahluwalia, Gustavo Roversi and Matthew M. Grabowski and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Tyler Alban

31 papers receiving 928 citations

Peers

Tyler Alban
Saket Jain United States
Stephanie Smith‐Berdan United States
Maria Georganaki Sweden
Erika Zonari Italy
Maya Zigler United States
Robert Tressler United States
Helena Kiefel Germany
Kabir A. Khan United Kingdom
François Lassailly United Kingdom
Dongqin Zhu China
Saket Jain United States
Tyler Alban
Citations per year, relative to Tyler Alban Tyler Alban (= 1×) peers Saket Jain

Countries citing papers authored by Tyler Alban

Since Specialization
Citations

This map shows the geographic impact of Tyler Alban's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tyler Alban with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tyler Alban more than expected).

Fields of papers citing papers by Tyler Alban

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tyler Alban. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tyler Alban. The network helps show where Tyler Alban may publish in the future.

Co-authorship network of co-authors of Tyler Alban

This figure shows the co-authorship network connecting the top 25 collaborators of Tyler Alban. A scholar is included among the top collaborators of Tyler Alban based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tyler Alban. Tyler Alban is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jurić, Ivan, Salendra Singh, Patricia Rayman, et al.. (2025). Responses to checkpoint inhibition in metastatic triple negative breast cancer driven by divergent myeloid phenotypes. Communications Medicine. 5(1). 180–180.
2.
Jurić, Ivan, Emily E. Fink, Arvind Ravi, et al.. (2025). Single-cell RNA-sequencing of BCG naïve and recurrent non-muscle invasive bladder cancer reveals a CD6/ALCAM-mediated immune-suppressive pathway. npj Precision Oncology. 9(1). 318–318.
3.
Verma, Ruchika, Tyler Alban, Mojgan Mokhtari, et al.. (2024). Sexually dimorphic computational histopathological signatures prognostic of overall survival in high-grade gliomas via deep learning. Science Advances. 10(34). eadi0302–eadi0302. 4 indexed citations
4.
Alban, Tyler, Vladimir Makarov, Shira Ronen, et al.. (2024). Genomic Landscape of Superficial Malignant Peripheral Nerve Sheath Tumor. Laboratory Investigation. 105(2). 102183–102183. 1 indexed citations
5.
Ta, Hieu Minh, Keman Zhang, Tyler Alban, et al.. (2024). LRIG1 engages ligand VISTA and impairs tumor-specific CD8 + T cell responses. Science Immunology. 9(95). eadi7418–eadi7418. 23 indexed citations
6.
Stabellini, Nickolas, Paul G. Pavicic, Pingfu Fu, et al.. (2023). Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research. 30(1). 82–93. 8 indexed citations
7.
Alban, Tyler, Nadeem Riaz, Vlad Makarov, et al.. (2023). Abstract 1125: Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab. Cancer Research. 83(7_Supplement). 1125–1125. 1 indexed citations
8.
Zhang, Keman, Amin Zakeri, Tyler Alban, et al.. (2023). 935 VISTA regulates the differentiation of myeloid-derived suppressor cells by STAT3-dependent modulation of arginase-1 and iNOS expression and mitochondrial function. SHILAP Revista de lepidopterología. A1039–A1039. 1 indexed citations
9.
Weber, Jeffrey K., Joseph A. Morrone, Seung-Gu Kang, et al.. (2023). Unsupervised and supervised AI on molecular dynamics simulations reveals complex characteristics of HLA-A2-peptide immunogenicity. Briefings in Bioinformatics. 25(1). 4 indexed citations
10.
Otvos, Balint, Tyler Alban, Matthew M. Grabowski, et al.. (2021). Preclinical Modeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes in Immunophenotype that are Associated with Tumor Growth and Outcome. Clinical Cancer Research. 27(7). 2038–2049. 23 indexed citations
11.
Swaidani, Shadi, Ann S. Kim, Bicky Thapa, et al.. (2021). Increased incidence of venous thromboembolism with cancer immunotherapy. Med. 2(4). 423–434.e3. 84 indexed citations
12.
Turaga, Soumya M., Daniel J. Silver, Defne Bayık, et al.. (2020). JAM-A functions as a female microglial tumor suppressor in glioblastoma. Neuro-Oncology. 22(11). 1591–1601. 28 indexed citations
13.
Alban, Tyler, Yujun Chen, Daniel J. Silver, et al.. (2020). Identifying conserved molecular targets required for cell migration of glioblastoma cancer stem cells. Cell Death and Disease. 11(2). 152–152. 21 indexed citations
14.
Bayık, Defne, Adam Lauko, Gustavo Roversi, et al.. (2020). Hepatobiliary malignancies have distinct peripheral myeloid-derived suppressor cell signatures and tumor myeloid cell profiles. Scientific Reports. 10(1). 18848–18848. 18 indexed citations
15.
Alban, Tyler, Defne Bayık, Balint Otvos, et al.. (2020). Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression. Frontiers in Immunology. 11. 1191–1191. 105 indexed citations
16.
Jimenez‐Pascual, Ana, James S. Hale, Daniel J. Silver, et al.. (2019). ADAMDEC1 Maintains a Growth Factor Signaling Loop in Cancer Stem Cells. Cancer Discovery. 9(11). 1574–1589. 56 indexed citations
17.
Mulkearns-Hubert, Erin E., Luke A. Torre-Healy, Daniel J. Silver, et al.. (2019). Development of a Cx46 Targeting Strategy for Cancer Stem Cells. Cell Reports. 27(4). 1062–1072.e5. 29 indexed citations
18.
Peereboom, David M., Tyler Alban, Matthew M. Grabowski, et al.. (2019). Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells. JCI Insight. 4(22). 88 indexed citations
19.
Dashzeveg, Nurmaa K., Rokana Taftaf, Erika K. Ramos, et al.. (2017). New Advances and Challenges of Targeting Cancer Stem Cells. Cancer Research. 77(19). 5222–5227. 16 indexed citations
20.
Nelson, Courtney M., Sumeda Nandadasa, Noriko Aramaki‐Hattori, et al.. (2017). Stromal Versican Regulates Tumor Growth by Promoting Angiogenesis. Scientific Reports. 7(1). 17225–17225. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Saket Jain Breakdown of academic impact, for papers by Stephanie Smith‐Berdan Breakdown of academic impact, for papers by Maria Georganaki Breakdown of academic impact, for papers by Erika Zonari Breakdown of academic impact, for papers by Maya Zigler Breakdown of academic impact, for papers by Robert Tressler Breakdown of academic impact, for papers by Helena Kiefel Breakdown of academic impact, for papers by Kabir A. Khan Breakdown of academic impact, for papers by François Lassailly Breakdown of academic impact, for papers by Dongqin Zhu
Rankless by CCL
2026